Plain-English translation of NCT06434896 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a blood test that detects tiny pieces of tumor DNA can help doctors make better decisions about who needs chemotherapy after colon cancer surgery. The blood test looks for circulating tumor DNA (ctDNA) — fragments of cancer genetic material in the bloodstream — to identify which patients are at higher risk of cancer returning. Half of the patients will have their blood test results shared with their doctor to guide treatment decisions, while the other half will receive standard follow-up care without knowing their blood test results.
Currently, doctors treat all stage II colon cancer patients the same way after surgery, even though many will never have their cancer return and may not need chemotherapy. This trial aims to see if the blood test can identify which patients truly need the medication and which ones can safely avoid it, potentially reducing unnecessary side effects.
You likely qualify if…
You likely don't qualify if…
You will have blood samples collected before surgery, right after surgery, and during follow-up visits as part of the larger study. If you are randomly assigned to the blood test group, your blood will be tested for tumor DNA and your doctor will receive the results to help decide whether to offer you 3 months of chemotherapy. If you are assigned to the standard care group, your blood will still be collected but the results will not be shared with your doctor, and you will receive routine follow-up care.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
Netherlands